Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant.

Saved in:
Bibliographic Details
Title: Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant.
Authors: Nielsen JC; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Woodhead JL; Simulations Plus, Inc., Research Triangle Park, North Carolina, USA., Howell BA; Simulations Plus, Inc., Research Triangle Park, North Carolina, USA., Shoda LKM; Simulations Plus, Inc., Research Triangle Park, North Carolina, USA., Parasrampuria DA; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Huang J; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Iwai M; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Ottery FD, Wang X; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., English M; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Miyazaki K; Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA., Watkins PB; University of North Carolina, Chapel Hill, North Carolina, USA.
Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2026 Apr; Vol. 119 (4), pp. 1016-1024. Date of Electronic Publication: 2026 Jan 16.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-6535
DOI:10.1002/cpt.70194